在甲基胺神经毒性中VMAT2与CDCrel-1和帕金的相互作用
Heli Chauhan1, Nicholas J Carruthers2,3, Paul M Stemmer1,2
1Department of Pharmaceutical Sciences, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, 259 Mack Ave., Detroit, MI 48201, USA.
International journal of molecular sciences
|December 17, 2024
概括
甲基胺使用障碍会导致神经系统问题. 这项研究揭示了帕金素功能障碍如何影响多巴胺储存,以及老鼠如何影响多巴胺储存.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 分子生物学分子生物学
背景情况:
- 甲基胺 (METH) 的滥用在美国是一个日益严重的公共卫生问题,对于METH使用障碍 (MUD) 没有批准的治疗方法.
- 使用METH导致神经毒性,影响神经功能,帕金蛋白功能障碍与这些影响有关.
- 帕金功能障碍对条状多巴胺基 (DAergic) 终端中多巴胺 (DA) 储存能力的影响尚不清楚.
研究的目的:
- 在METH神经毒性的背景下,研究帕金,其基质CDCrel-1和VMAT2之间的关系.
- 检查METH暴饮暴食暴露如何改变CDCrel-1和VMAT2之间的相互作用,以及它们的水平和定位.
- 通过分析DAergic神经元中的分子变化来探索对METH神经毒性反应的个体差异.
主要方法:
- 雄性Sprague Dawley大鼠被给予大量的METH或盐水,并在治疗后1或24小时牺牲.
- 蛋白质组分析用于识别与VMAT2.2相关的蛋白质.
- 评估了CDCrel-1和VMAT2的水平和亚细胞局部.
主要成果:
- 这项研究是第一个在老鼠条体中证明CDCrel-1和VMAT2之间的相互作用的研究.
- 暴食METH暴露显著改变了CDCrel-1和VMAT2的相互作用,以及CDCrel-1的水平和亚细胞分布.
- 蛋白质组分析显示,VMAT2相关蛋白质中参与外细胞/内细胞和应激反应的蛋白质的上调调节.
结论:
- 达尔基神经元对METH诱导的毒性表现出适应性反应,包括增加细胞内和自,这在个体之间有很大的差异.
- 这些发现突出了CDCrel-1,VMAT2和其他蛋白质在对METH暴露的反应中的动态相互作用.
- 了解METH神经毒性反应中的单个分子差异可以为MUD的向治疗方法的开发提供信息.
相关概念视频
01:29Drugs Affecting Neurotransmitter Synthesis
1.3K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.3K
01:21Drugs Affecting Neurotransmitter Release or Uptake
941
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
941
01:24Parkinson's Disease: Treatment
216
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
216
01:25Adrenergic Agonists: Indirect-Acting Agents
1.5K
Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
1.5K